PT Tempo Scan Pacific Tbk is a leading Indonesian pharmaceutical company specializing in the production of prescription drugs and over-the-counter products. Its competitive position is bolstered by a diverse portfolio of proprietary products and strong distribution networks across Southeast Asia, particularly in Indonesia, where it holds significant market share in various therapeutic categories.
Tempo Scan generates revenue primarily through the sale of prescription medications and consumer health products. The company benefits from strong brand recognition and a robust distribution network, allowing it to maintain pricing power in a competitive market. Its focus on R&D for new drug formulations enhances its competitive advantage.
Regulatory approvals for new drug formulations
Changes in healthcare policies affecting drug pricing
Market share gains in key therapeutic areas
Fluctuations in raw material costs impacting margins
Regulatory changes affecting drug approval processes
Technological disruption in drug manufacturing and delivery
Increased competition from generic drug manufacturers
Potential market entry of multinational pharmaceutical companies
Low liquidity risk due to a high current ratio of 3.33
Potential risks associated with R&D investments not yielding expected returns
moderate - the company's performance is somewhat linked to GDP growth, as increased consumer spending can lead to higher demand for healthcare products.
The company has minimal sensitivity to interest rates due to low debt levels (Debt/Equity of 0.12), which limits financing costs and maintains stable valuation multiples.
minimal
growth - investors may be attracted to the company's potential for revenue growth through new product launches and market expansion.
moderate - the stock has shown stable performance with a low beta relative to the market.